Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report | Zendy

Takayuki Kosaka | Zendy; Toshiki Yajima | Zendy; Ei Yamaki | Zendy; Seshiru Nakazawa | Zendy; Kenji Tomizawa | Zendy; Ryoichi Onozato | Zendy; Ayako Yamazaki | Zendy; Junko Hirato | Zendy; Yasushi Yatabe | Zendy; Kimihiro Shimizu | Zendy; Akira Mogi | Zendy; Ken Shirabe | Zendy

Open Access

Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report

Author(s) -

Takayuki Kosaka,

Toshiki Yajima,

Ei Yamaki,

Seshiru Nakazawa,

Kenji Tomizawa,

Ryoichi Onozato,

Ayako Yamazaki,

Junko Hirato,

Yasushi Yatabe,

Kimihiro Shimizu,

Akira Mogi,

Ken Shirabe

Publication year - 2019

Publication title -

molecular and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.442

H-Index - 7

eISSN - 2049-9469

pISSN - 2049-9450

DOI - 10.3892/mco.2019.1892

Subject(s) - crizotinib , anaplastic lymphoma kinase , adenocarcinoma , alk inhibitor , lung cancer , medicine , cancer research , oncology , lung , oncogene , gene rearrangement , cancer , biology , cell cycle , gene , genetics , malignant pleural effusion

Anaplastic lymphoma kinase (ALK) gene rearrangements are identified in approximately 5% of patients with non-small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year, owing to the development of resistance. Herein we present a case of variant type 2 ALK -rearranged lung adenocarcinoma recurrence with multiple lung metastasis that maintained complete response over 5 years with crizotinib, which is the first approved ALK inhibitor. The efficacy of crizotinib may vary among ALK fusion variants and thus, variant type may represent an important factor in guiding the treatment strategy for ALK -rearranged lung adenocarcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research